HOME CONTACT ABOUT PRODUCT PIPELINE RESOURCES PARTNERING INVESTORS MEDIA CAREERS ABOUT MANAGEMENT TEAM BOARD OF DIRECTORS OUR PURPOSE, MISSION & VALUES HISTORY Acadia is trailblazing breakthroughs in neuroscience to elevate life. Acadia aspires to enable brighter moments for patients and their loved ones. For more than 25 years we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson’s disease psychosis. Our late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research we are exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders. For more information, follow us on LinkedIn. News November 16, 2021 Acadia Pharmaceuticals and StoryCorps Collaborate to Launch Yours, Truly – a Multicultural Storytelling Campaign to Bring Greater Awareness to Parkinson’s Disease Non-Motor Symptoms Company Information Annual Report Events & Presentations Publication Spotlight Pimavanserin for patients with Parkinson’s disease psychosis: a randomized, placebo-controlled phase 3 trial. The Lancet, 383, 533-540 (2014). Parkinson’s disease psychosis, which includes hallucinations and delusions, is frequent and debilitating in people with Parkinson’s disease. We aimed to assess safety and efficacy of pimavanserin, a selective serotonin 5-HT2A inverse agonist, in this population. Link to full article Print page Share PRIVACY COOKIES PRIVACY SHIELD TERMS EMAIL © 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our .

HOME CONTACT ABOUT PRODUCT PIPELINE RESOURCES PARTNERING INVESTORS MEDIA CAREERS Board of Directors EXPAND ALL STEPHEN R. BIGGAR, M.D., PH.D., Chairman JULIAN C. BAKER LAURA A. BREGE JAMES M. DALY STEPHEN R. DAVIS ELIZABETH GAROFALO, M.D. EDMUND P. HARRIGAN, M.D. DANIEL B. SOLAND ABOUT MANAGEMENT TEAM BOARD OF DIRECTORS OUR PURPOSE, MISSION & VALUES HISTORY Print page Share PRIVACY COOKIES PRIVACY SHIELD TERMS EMAIL © 2021 Acadia Pharmaceuticals Inc. Acadia and NUPLAZID are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. By using this website without changing your cookie settings in your browser, you agree to our use of cookies. For further details on cookies, how we use cookies and how to delete or block the use of cookies, please read our .